Where Will TJX Companies Stock Be in 10 Years?
Off-price retail is as popular as ever thanks to social…
Sell
3
ARTV Quote, Financials, Valuation and Earnings
Last price:
$6.52
Seasonality move
:
--
Day range:
$6.50 - $7.12
52-week range:
$6.50 - $17.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.79x
P/B ratio:
0.57x
Volume:
68.1K
Avg. volume:
67.3K
1-year change:
--
Market cap:
$114.8M
Revenue:
$33.5M
EPS (TTM):
-$3.08
Analysts' Opinion
-
Consensus RatingArtiva Biotherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.00, Artiva Biotherapeutics has an estimated upside of 221.59% from its current price of $6.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $6.53.
Fair Value
-
According to the consensus of 4 analysts, Artiva Biotherapeutics has 221.59% upside to fair value with a price target of $21.00 per share.
ARTV vs. S&P 500
-
Over the past 5 trading days, Artiva Biotherapeutics has underperformed the S&P 500 by -32.14% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Artiva Biotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Artiva Biotherapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Artiva Biotherapeutics reported revenues of $251K.
Earnings Growth
-
Artiva Biotherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Artiva Biotherapeutics reported earnings per share of -$0.79.
Enterprise value:
-31.8M
EV / Invested capital:
--
Price / LTM sales:
46.79x
EV / EBIT:
--
EV / Revenue:
31.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-38.54%
Net Income Margin (TTM):
-1351.52%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-5773.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $26.7M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$34.3M | -$61M | $10.8M | -$18.3M | |
| EBITDA | -- | -$32.5M | -$58.6M | $11.4M | -$17.7M | |
| Diluted EPS | -- | -$3.57 | -$3.51 | $1.20 | -$0.92 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $171.5M | -- | -- | $150.6M | |
| Total Assets | -- | $178.2M | -- | -- | $225.6M | |
| Current Liabilities | -- | $15.6M | -- | -- | $13.3M | |
| Total Liabilities | -- | $257.4M | -- | -- | $24.6M | |
| Total Equity | -- | -$79.2M | -- | -- | $201M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$46.4M | -$51.1M | -$10.7M | -$11.6M | |
| Cash From Investing | -- | -$23.9M | -$122.2M | -$493K | -$130.6M | |
| Cash From Financing | -- | $23.1M | $163.2M | $23.4M | $163.9M | |
| Free Cash Flow | -- | -$49.6M | -$52.3M | -$10.9M | -$11.7M | |
ARTV
Sector
Market Cap
$114.8M
$44.9M
Price % of 52-Week High
37.72%
46.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
--
-33.54%
Beta (5-Year)
--
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$8.16
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Sell
Level
9.71 - 13.49
Chaikin Money Flow
Buy
Level
2.5M
20-day SMA
Sell
Level
$9.54
Relative Strength Index (RSI14)
Sell
Level
25.32
ADX Line
Sell
Level
29.91
Williams %R
Buy
Level
-99.4059
50-day SMA
Sell
Level
$10.94
MACD (12, 26)
Sell
Level
-1.12
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
2.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-9.6475)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (14.2934)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
Stock Forecast FAQ
In the current month, ARTV has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARTV average analyst price target in the past 3 months is $21.00.
-
Where Will Artiva Biotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Artiva Biotherapeutics share price will rise to $21.00 per share over the next 12 months.
-
What Do Analysts Say About Artiva Biotherapeutics?
Analysts are divided on their view about Artiva Biotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Artiva Biotherapeutics is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is Artiva Biotherapeutics's Price Target?
The price target for Artiva Biotherapeutics over the next 1-year time period is forecast to be $21.00 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARTV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Artiva Biotherapeutics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARTV?
You can purchase shares of Artiva Biotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Artiva Biotherapeutics shares.
-
What Is The Artiva Biotherapeutics Share Price Today?
Artiva Biotherapeutics was last trading at $6.52 per share. This represents the most recent stock quote for Artiva Biotherapeutics. Yesterday, Artiva Biotherapeutics closed at $6.53 per share.
-
How To Buy Artiva Biotherapeutics Stock Online?
In order to purchase Artiva Biotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will CVS Health Stock Recover?
It’s been a treacherous journey for CVS Health Corporation (NYSE:CVS)…
Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
